Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing surveillance of Vfend IV safety and efficacy
2017-000197-11Phase 4
- Sponsor
- Pfizer
- Start
- Mar 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of voriconazole in invasive aspergillosis (IA), allescheriosis, fusariosis and 2 more, sponsored by Pfizer. Primary endpoint: Percentage of participants with categorical clinical response.
02
Drugs
voriconazole
03
Conditions
invasive aspergillosis (IA)allescheriosisfusariosiscandidemiacandidiasis
Beyond the preview
Go deeper on 2017-000197-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000197-11.